These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29628214)

  • 41. Neuroleptic malignant syndrome, amitriptyline, and thioridazine.
    Corrigan FM; Coulter F
    Biol Psychiatry; 1988 Feb; 23(3):320-1. PubMed ID: 3337866
    [No Abstract]   [Full Text] [Related]  

  • 42. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy.
    Keyser DL; Rodnitzky RL
    Arch Intern Med; 1991 Apr; 151(4):794-6. PubMed ID: 1672810
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
    Kuno S
    Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Neuroleptic malignant syndrome with clozapine monotherapy and benign hyperthermia after resolving neuroleptic malignant syndrome with clozapine. Two case reports].
    Vetter P; Proppe D; Hoppe-Seyler S
    Nervenarzt; 1991 Jan; 62(1):55-7. PubMed ID: 2027422
    [No Abstract]   [Full Text] [Related]  

  • 45. Neuroleptic malignant like syndrome in two patients on cholinesterase inhibitors.
    Grace JB; Thompson P
    Int J Geriatr Psychiatry; 2006 Feb; 21(2):193-4. PubMed ID: 16440373
    [No Abstract]   [Full Text] [Related]  

  • 46. Biopterin metabolism in patients with malignant syndrome.
    Ichinose H; Ohye T; Shinotoh H; Arai K; Yamazaki S; Mizuta E; Kuno S; Nagatsu T
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S11-4. PubMed ID: 12735910
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Case study: cerebrovascular parkinsonism with levodopa addiction.
    Lily O; Al-Din A
    J Neurol Neurosurg Psychiatry; 2004 Sep; 75(9):1365-6. PubMed ID: 15314141
    [No Abstract]   [Full Text] [Related]  

  • 48. Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
    Hermesh H; Sirota P; Eviatar J
    Biol Psychiatry; 1989 Apr; 25(7):962-5. PubMed ID: 2720007
    [No Abstract]   [Full Text] [Related]  

  • 49. Psychotropic discontinuation symptoms: a case of withdrawal neuroleptic malignant syndrome.
    Stonecipher A; Galang R; Black J
    Gen Hosp Psychiatry; 2006; 28(6):541-3. PubMed ID: 17088172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neuroleptic malignant syndrome following levomepromazine discontinuation.
    Tanii H; Saka K; Inoue K; Okada M
    J Neuropsychiatry Clin Neurosci; 2010; 22(2):E16. PubMed ID: 20463130
    [No Abstract]   [Full Text] [Related]  

  • 51. Neuroleptic malignant syndrome related to a switch to perospirone and anticholinergic withdrawal.
    Tanii H; Fujita K; Okazaki Y
    Am J Psychiatry; 2006 Mar; 163(3):547-8. PubMed ID: 16513884
    [No Abstract]   [Full Text] [Related]  

  • 52. [The neuroleptic malignant syndrome].
    Duarte J; García Viejo MA; García Miguel FJ; Sempere AP
    Med Clin (Barc); 1994 Oct; 103(14):558. PubMed ID: 7799673
    [No Abstract]   [Full Text] [Related]  

  • 53. Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient.
    Shimada J; Sakakibara R; Uchiyama T; Liu Z; Yamamoto T; Ito T; Mori M; Asahina M; Hattori T
    Eur J Neurol; 2006 Mar; 13(3):306-7. PubMed ID: 16618352
    [No Abstract]   [Full Text] [Related]  

  • 54. Parkinsonism-hyperpyrexia syndrome due to abrupt withdrawal of amantadine.
    Cheung YF; Hui CH; Chan JH
    Hong Kong Med J; 2011 Apr; 17(2):167-8. PubMed ID: 21471604
    [No Abstract]   [Full Text] [Related]  

  • 55. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.
    Takubo H; Harada T; Hashimoto T; Inaba Y; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S31-41. PubMed ID: 12735913
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Withdrawal NMS after drug treatment.
    Merriam AE
    Biol Psychiatry; 1988 Jul; 24(3):368-9. PubMed ID: 3401532
    [No Abstract]   [Full Text] [Related]  

  • 57. Neuroleptic malignant syndrome-like, or--dopaminergic malignant syndrome--due to levodopa therapy withdrawal. Clinical features in 11 patients.
    Serrano-Dueñas M
    Parkinsonism Relat Disord; 2003 Jan; 9(3):175-8. PubMed ID: 12573874
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):510-1; author reply 511. PubMed ID: 14966183
    [No Abstract]   [Full Text] [Related]  

  • 59. Neuroleptic malignant syndrome following withdrawal of amantadine in a patient with influenza A encephalopathy.
    Ito T; Shibata K; Watanabe A; Akabane J
    Eur J Pediatr; 2001 Jun; 160(6):401. PubMed ID: 11421428
    [No Abstract]   [Full Text] [Related]  

  • 60. [Levodopa withdrawal symptoms in a non-Parkinsonian patient].
    Cabo-López I; García-Bermejo P; García-Ruiz PJ
    Rev Neurol; 2007 Aug 1-15; 45(3):190. PubMed ID: 17661281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.